Beijing Scitop Bio-tech Co., Ltd.
SZSE:300858.SZ
19.72 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 302.793 | 299.242 | 369.165 | 364.618 | 339.159 | 308.099 | 317.897 | 283.756 | 260.621 | 185.414 |
| Cost of Revenue
| 126.411 | 135.91 | 177.29 | 181.167 | 175.274 | 150.634 | 160.725 | 150.551 | 144.515 | 111.061 |
| Gross Profit
| 176.382 | 163.332 | 191.875 | 183.451 | 163.885 | 157.465 | 157.172 | 133.205 | 116.107 | 74.353 |
| Gross Profit Ratio
| 0.583 | 0.546 | 0.52 | 0.503 | 0.483 | 0.511 | 0.494 | 0.469 | 0.445 | 0.401 |
| Reseach & Development Expenses
| 36.327 | 34.194 | 22.089 | 27.151 | 17.573 | 14.753 | 15.837 | 12.587 | 9.389 | 6.042 |
| General & Administrative Expenses
| 9.189 | 2.514 | 7.63 | 15.781 | 6.344 | 4.65 | 7.264 | 5.99 | 65.876 | 13.177 |
| Selling & Marketing Expenses
| 25.334 | 22.832 | 27.232 | 25.007 | 18.069 | 16.444 | 13.341 | 12.165 | 16.478 | 5.429 |
| SG&A
| 34.523 | 25.346 | 34.862 | 40.788 | 24.413 | 21.094 | 20.605 | 18.155 | 82.354 | 18.606 |
| Other Expenses
| -3.93 | 0 | -1.921 | -0.531 | -4.535 | -0.132 | -0.159 | -0.334 | 4.65 | 0.742 |
| Operating Expenses
| 66.92 | 60.73 | 76.089 | 89.027 | 53.471 | 48.796 | 49.825 | 43.322 | 93.56 | 25.696 |
| Operating Income
| 109.463 | 102.602 | 127.577 | 124.704 | 117.711 | 110.716 | 107.064 | 87.837 | 20.122 | 46.524 |
| Operating Income Ratio
| 0.362 | 0.343 | 0.346 | 0.342 | 0.347 | 0.359 | 0.337 | 0.31 | 0.077 | 0.251 |
| Total Other Income Expenses Net
| -0.635 | -0.561 | -1.921 | -0.531 | -4.535 | -0.132 | -0.159 | -0.334 | 4.65 | -0.595 |
| Income Before Tax
| 108.828 | 102.041 | 125.656 | 124.174 | 113.175 | 110.584 | 106.905 | 87.503 | 24.772 | 47.265 |
| Income Before Tax Ratio
| 0.359 | 0.341 | 0.34 | 0.341 | 0.334 | 0.359 | 0.336 | 0.308 | 0.095 | 0.255 |
| Income Tax Expense
| 14.472 | 8.561 | 15.764 | 14.634 | 16.599 | 17.3 | 14.985 | 16.328 | 13.277 | 12.247 |
| Net Income
| 94.356 | 93.48 | 109.891 | 109.539 | 96.577 | 93.284 | 91.919 | 71.348 | 11.535 | 35.018 |
| Net Income Ratio
| 0.312 | 0.312 | 0.298 | 0.3 | 0.285 | 0.303 | 0.289 | 0.251 | 0.044 | 0.189 |
| EPS
| 0.36 | 0.35 | 0.49 | 0.49 | 0.43 | 0.42 | 0.55 | 0.44 | 0.096 | 0.4 |
| EPS Diluted
| 0.36 | 0.35 | 0.49 | 0.49 | 0.43 | 0.42 | 0.55 | 0.44 | 0.096 | 0.4 |
| EBITDA
| 135.233 | 123.925 | 144.751 | 128.343 | 124.269 | 116.797 | 109.124 | 91.838 | 24.745 | 49.454 |
| EBITDA Ratio
| 0.447 | 0.414 | 0.392 | 0.352 | 0.366 | 0.379 | 0.343 | 0.324 | 0.095 | 0.267 |